This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
QUICK READ: Patients are returning to their doctor’s office, and it’s not uncommon for appointments, or routine visits, to be scheduled weeks or months in advance. When I sent an email to my doctor’s office, I was shocked when she said the earliest appointment she had for physicals was in September.
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
Relyvrio, a drug developed by Amylyx Pharmaceuticals, is in high demand in ALS clinics across the U.S. Though some patients are already getting it, insurance coverage and out-of-pocket costs remain a source of anxiety.
Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.
The patient, who has a severe shellfish allergy, recovered quickly with treatment. Until now, reports of severe reactions had been linked to the Pfizer vaccine.
A multidistrict litigation has been started by more than 1,700 people who have used Elmiron for a prolonged period of time and have developed eyesight impairments in an effort to recover damages. A recurring question that the The post <strong>Can You Sue Your Doctor for Blindness Caused by Elmiron</strong>®<strong>?
The most desired information doctors now want is about patient assistance programs, with 49% saying they want pharma reps to provide that information. Most doctors sign on in the morning and see a snapshot of what’s happening by their specialty. doctors and 45% of all NPS and physician assistants as verified members.
David Davidson is leaving Bluebird bio after nearly a decade as the gene therapy developer's top doctor. His new home, Tessera, just raised $230 million to advance its "gene writing" research.
Researchers in the US have developed an artificial intelligence-based tool that is able to predict COVID-19 symptoms and suggest which FDA-approved drugs might be used to treat patients. The post AI tool may help doctors select best drugs for COVID patients appeared first on.
Medisafe, a leading digital therapeutics company specializing in digital companions, has been selected by UCB to develop branded digital drug companions for its antiepileptic medications, with greater capabilities to expand across additional brands. 1 in 26 people in the US will develop epilepsy at some point in their.
Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.
An international group of doctors and public health experts have joined the clamor for a moratorium on AI research until the development and use of the technology are properly regulated.
Wearable devices can alert patients to potential health issues that require a visit to the doctor. The challenge is getting to the doctor promptly without needing that maze that has become our healthcare system. A new patient, for example, to a cardiologist would require a full battery of tests and a wait time to see the doctor.
The artificial intelligence system is a dream for many doctors: It records their conversations with patients and automatically transcribes the notes into their computer systems. No need to bring a laptop to every patient visit, or spend hours afterward on documentation. Continue to STAT+ to read the full story…
Doctors have long asserted that prior authorization — the need to get approval from the patient’s insurer before proceeding with treatment — causes delays that can hurt patient care. Prior authorizations also exact a toll on doctors, who say the paperwork has gotten out of hand. Then there is prior authorization.
In the intervention arm, patients with a primary complaint of low back pain are referred to physical therapists and chiropractic doctors as first-line providers. The post March 15, 2023: IMPACt-LBP Enrolls First Patient in Study of Collaborative Care for Low Back Pain appeared first on Rethinking Clinical Trials.
In 2019, the OECD declared that developed countries’ plans to tackle the problem largely failed. But before the company can make Wegovy mainstream, it has to convince doctors to prescribe it and insurers and governments to pay for it. In addition, doctors may not be ready to prescribe the drug. Then there is the price.
Consumers would ask their doctor about an advertised prescription drug in a perfect world. Most patients said they had done more research online or talked to other patients about their experience before asking their doctor about the brand. In our REAL world, that isn’t the way it happens. The research was straightforward.
The onset of wrong, inaccurate, or confusing medical information forces people to go online or talk to their doctor about treatment options. Visting my doctor for my annual physical, I noticed huge LCD screens in each exam room with rotating ads for everything from prescription drugs to vitamins.
According to a report on CNN.com “Pfizer said it is seeing waning immunity from its coronavirus vaccine and says it is picking up its efforts to develop a booster dose that will protect people from variants.” My doctor said she is waiting for more clinical data and has already had patients ask about a booster shot.
Apple, with its new privacy requirements, is challenging app developers and brands while Facebook cries fowl. First there is the cost of developing an app. If, for existence, a pharma developed app requires patients to “check-in” everyday it could be a reminder that they are living with a chronic health issue.
After a year of pandemic-delayed medical tr eatments, doctors are seeing more cases of advanced illnesses. To their doctors, will we see a huge increase in MRI and other tests? I love the industry, and although I want to see some changes, I know there are many good people trying every day to make it happen.
From mobile medical apps and software that support the clinical decisions doctors make every day to artificial intelligence and machine learning, digital technology has been driving a revolution in health care. However, doctors should embrace patients who are keen to manage their chronic conditions and support them.
Patients who have digestive symptoms only after eating red meat may have developed an allergy caused by ticks. Previously, doctors looked for symptoms such as rashes, hives and breathing troubles. Image credit: Getty Images)
The days of someone seeing an ad for a prescription drug and rushing to ask their doctor about it have replaced the quest for more information, usually online. Two doctors I chatted with said they are getting requests from patients who want to lose weight and do not have diabetes.
Researchers from Rutgers and other universities have developed a behavioral model that explains a long-standing health care mystery: Why do so many terminally ill patients undergo intense last-ditch treatments with little chance of meaningful life extension?
TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.
It took a panel of almost 400 independent-thinking scientists, doctors, and representatives of community groups from more than 100 countries (we were among the co-chairs) some 14 months to develop and agree on these recommendations. There have been times when we wondered if it was worth the effort. Read the rest…
Tech startup Proximie has raised $80 million in third-round financing that will be used to further develop its augmented reality platform, which allows surgeons to share best practices with other clinicians anywhere in the world. The post Digital operating room developer Proximie raises $80m appeared first on.
You need people who can understand what your brand is trying to do and develop an online strategy that checks all the boxes. Sure patients are staying away from doctors’ offices now but do we know for sure that trend will last? It’s why pharma has to provide links to credible online health information.
5ive: People are interacting with their doctors in new ways. There is no longer a need to go to the doctor to ask for an Rx renewal. Omnichannel marketing, for example, depends on the audience size and the message development. The pandemic led to more people going online for health information, and that trend will continue.
QUICK READ : Obesity is associated with a higher risk of developing severe symptoms and complications of coronavirus disease, independent of other illnesses, such as cardiovascular disease. While other developed countries were able to flatten the curve, reduce transmissions, and get back to some semblance of normal life, the U.S.
The FDA’s Office of Neuroscience, which oversees the development of new ALS drugs in the U.S., “has repeatedly failed to take aggressive steps to greenlight these experimental therapies,” Woods wrote in his First Opinion essay, “As a pediatric cancer researcher, I admired the FDA.
The money that GSK is using on TV ads for this product could have used to develop a real kick-ass digital program. One of the features I do like is the “find a doctor” feature. The online health seeker just enters his/her zip code and can find a doctor to help diagnose possible sever asthma.
But in a rush to develop some apps, there are dangers. Vastaamo has filed for bankruptcy but left many Finns wary of telling doctors personal details, says Joni Siikavirta, a lawyer representing the company’s patients. For now, however, it’s “try this app at your own risk” as developers look to cash in.
Biogen will partner with Roche on the development, and potential sale of a promising cancer drug the Swiss pharma is advancing for several types of lymphoma, announcing Tuesday it’s exercised an option to share rights to the treatment. Now Biogen wants to partner with Roche to develop a cancer drug?
Patients are finally returning to their doctors, and some DTC people really believe they will go to their doctor and ask for an Rx. I’m surprised that an agency hasn’t developed an app to monitor social media posts around certain keywords for pharma.
2wo: Telehealth will find use among patients because of convenience – No need to go to the doctor to ask for an Rx renewal and, in some cases, a new Rx. It’saper to bet on a small molecule in development than add more money to R&D.
At the same time, experts are saying developers in the field need to double down on securing clinical data to allow for its continued maturation. But while appealing, the prospects of developing a merged approach that combines both digital and pharmacological therapeutics remain challenging.
An exciting development presented itself. As a couple of doctors told us, “there is so much information trying to get to us that it’s getting harder to filter out what I need and what’s just typical marketing talk.” We found that some of the toppling findings weren’t relevant.
An email campaign, with helpful tips and recommendations of living with a chronic health condition, would be widely accepted by patients but one email doesn’t fit all segments, and developing content is too time-consuming for pharma. The downside is that it has to be done on Internet time, not according to internal processes.
Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. Developing best-in-class speciality enzymes. After joint development, screening, and proof of concept, we purify the selected enzyme intermediate from Novozymes under cGMP conditions.
FINDING : Doctors across the globe report a significant increase in the consumption of online medical content compared to pre-pandemic levels. Drug companies need to develop a model in which there is continuous improvement in online interactions. Medscape Detailed Findings.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content